Accessibility Menu
Medicus Pharma logo

Medicus Pharma(NASDAQ) MDCX

Market Cap$3.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-93%
5 YearN/A
1 Year-88%
1 Month-35%
$0.31
+4.45%
+0.01Today
Medicus Pharma last closing stock price
MetricPriceDate
Last closeUSD 0.302026-08-05
Medicus Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9.93%USD 0.272026-07-29
1 month-35.48%USD 0.462026-07-06
3 month-5.48%USD 0.312026-05-07
Year to date-80.6%USD 1.532025-12-31
1 year-87.68%USD 2.412025-08-05
Since inception-92.76%USD 4.102024-01-26

Medicus Pharma Financials at a Glance

Market Cap

$3.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$36.93M

EPS (TTM)

-$1.78

P/E Ratio

-0.17

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.31

Volume

1,597,168.264

Open

$0.31

Previous Close

$0.30

Daily Range

$0.30 - $0.32

52-Week Range

$0.25 - $3.05

Estimated Earnings Date

N/A

MDCX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medicus Pharma

Medicus Pharma develops new treatments for skin and prostate cancer. Its products aim to make therapies less invasive for patients. The company focuses on clinical research, not yet selling products to the public.

Products and Services

  • SkinJect: Microneedle patches deliver medicine directly to skin cancer sites; targets patients with non-melanoma skin cancers.
  • Antev: Teverelix, an injectable therapy for prostate cancer and urinary retention; designed for men with high cardiovascular risk.
  • AI Clinical Analytics: Uses artificial intelligence to analyze clinical trial data; supports faster and more precise research decisions.
  • Vaccine Co-Development: Partners with Helix Nanotechnologies to explore new vaccine delivery methods using microneedle technology.
  • Compassionate Access Programs: Works with patient groups to provide early access to experimental therapies for rare conditions.

Growth and Expansion

  • Acquired Antev Limited in August 2025, expanding into prostate cancer therapies.
  • Launched global clinical trials for SkinJect in the US, UK, and UAE in 2025.
  • Signed a non-binding agreement with Helix Nanotechnologies in 2025 for vaccine research.
  • Started an AI partnership with Reliant AI Inc. in 2025 to improve clinical data analysis.
  • Formed a collaboration with Gorlin Syndrome Alliance in 2025 for expanded patient access.

What Makes Medicus Pharma Stand Out

The company uses microneedle technology for targeted, less invasive drug delivery. It holds exclusive licenses for key patents from major universities. Medicus focuses on advancing therapies to mid-stage trials, then seeks partners for commercialization.

Five Things You Need to Know

  • Revenue was $0 in 2025, unchanged from 2024 and 2023.
  • Net loss was $35.4 million in 2025, up 216.1% from 2024.
  • Operating expenses rose to $34.4 million in 2025, up 207.4% year-over-year.
  • Cash and cash equivalents were $8.7 million as of December 31, 2025.

Bottom Line

Medicus Pharma remains a research-focused biotech with no commercial sales. Its strategy centers on innovation and partnerships to advance new therapies for cancer and related conditions.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

16

CEO

Raza Bokhari, MD, MBA

Website

www.medicuspharma.com

Headquarters

Conshohocken, PA 19428, CA

MDCX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-4086.31%

Return on Capital

-467.18%

Return on Assets

-497.30%

Earnings Yield

-5.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.82M

Volume

1.60M

Avg. Volume

2.21M

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$35.50M

EBITDA

-$37.11M

Operating Cash Flow

-$23.41M

Capital Expenditure

$3.00

Free Cash Flow

-$23.41M

Cash & ST Invst.

$6.37M

Total Debt

$169.62K

Medicus Pharma Performance Analysis

Medicus Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Medicus Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Medicus Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.16N/A
20232023-12-31USD -0.49202.9%
20242024-12-31USD -0.6941.3%
20252025-12-31USD -1.96184.1%
Medicus Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-2.4%
Q32025-09-30-160.5%
Q42025-12-3161.6%
Q12026-03-3148.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$3.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$219.20K

N/A

Employees

16

N/A

Net Income

-$6.59M

-29.2%

EBITDA

-$6.97M

-36.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$6.37M

+59.8%

Total Debt

$169.62K

-42.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$24.17K

-86.1%

Short Term Debt

$145.46K

+20.9%

Return on Assets

-4.97%

N/A

Return on Invested Capital

-24.10%

N/A

Free Cash Flow

-$6.51M

-65.2%

Operating Cash Flow

-$6.51M

-65.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SKYESkye Bioscience, Inc.
$0.57+1.35%
BRNSBarinthus Biotherapeutics plc
$0.57-0.02%
ALGSAligos Therapeutics, Inc.
$5.36+13.08%
COEPCoeptis Therapeutics Holdings, Inc.
$10.99-8.57%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$110.38+0.02%
NVDANvidia
$219.78+0.00%
SOUNSoundHound AI
$7.09+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.62-0.02%

Questions About MDCX

What is the current price of Medicus Pharma?

Medicus Pharma is trading at $0.31 per share.

What is the 52-week range for Medicus Pharma?

Over the past 52 weeks, Medicus Pharma has traded between $0.25 and $3.05.

How much debt does Medicus Pharma have?

As of the most recent reporting period, Medicus Pharma reported total debt of $1.82M.

How much cash does Medicus Pharma have on hand?

Medicus Pharma reported $4.56M in cash and cash equivalents in its most recent financial results.

What is Medicus Pharma’s dividend yield?

Medicus Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services